Clinical Trials on Granuloma, Plasma Cell in China

Total 4835 results

Kyorin University
Japan Clinical Oncology Group

Recruiting

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III (RE-GEND)

Recurrence | Glioblastoma | Progression

Japan
Incyte Corporation

Terminated

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma

Spain, France, United States, Italy, Japan, Ireland, Slovakia, Austria, Belgium, Canada, Finland, Germany, Poland, Portugal, Romania, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm | Anorexia | Advanced Malignant Solid Neoplasm

United States
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
AstraZeneca

Recruiting

First in Human Study of AZD9592 in Solid Tumors (EGRET)

Head and Neck Neoplasms | Colorectal Neoplasms | Advanced Solid Tumours | Carcinoma Non-small Cell Lung

United States, China, Korea, Republic of, Spain, Australia, Japan, Malaysia, Taiwan, Canada, France, Italy
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Bayer

Completed

Long-term Extension From RCC Phase II (11515)

Carcinoma, Renal Cell

Japan
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
AstraZeneca

Recruiting

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Carcinoma, Non-Small-Cell Lung | Gastric Cancer | Gastroesophageal Junction Cancer

United States, Canada, Spain, China, Japan, France, Turkey, Netherlands, Moldova, Republic of, Georgia
AstraZeneca

Active, not recruiting

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

Carcinoma, Non-Small-Cell Lung

Poland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
Janssen Research & Development, LLC

Recruiting

A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer (METalmark)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, China, Germany, United States, Brazil, Italy, Spain, France, Canada, Japan, Poland, Turkey, United Kingdom
Hoffmann-La Roche

Terminated

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)

Renal Cell Carcinoma

Korea, Republic of, United States, Canada, United Kingdom, Argentina, Australia, Belgium, Brazil, China, Denmark, Ireland, Spain, Japan, Netherlands, Chile, Czechia, Italy, France, Israel, Turkey, Germany, Austria, Taiwan, Serbia, Poland, Thailan... and more
Novartis Pharmaceuticals

Active, not recruiting

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Renal Cell Carcinoma | Colorectal Cancer | Gastroesophageal Cancer

United Kingdom, Australia, Belgium, Germany, Italy, Taiwan, Czechia, Israel, Spain, Japan, Singapore, Canada, Korea, Republic of, United States, Chile
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Russian Federation, Belgium, United States, Australia, Argentina, Brazil, Canada, China, Czechia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Taiwan, United Kingdom
Janssen Research & Development, LLC

Recruiting

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2)

Carcinoma, Non-Small-Cell Lung

Taiwan, United States, Korea, Republic of, Germany, France, China, Japan, Italy, Spain, Puerto Rico
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)

Renal Cell Carcinoma

Korea, Republic of, Spain, United States, Netherlands, Ireland, Canada, United Kingdom, Poland, Italy, Australia, Russian Federation, Belgium, Israel, France, Greece, Czechia, Switzerland, Austria, Germany, Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Exelixis

Active, not recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

Renal Cell Carcinoma

United States, Japan, Brazil, Argentina, Australia, Chile, Czechia, Germany, Greece, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Spain, Turkey, United Kingdom
GOG Foundation
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Recurrent Endometrial Clear Cell Adenocarcinoma | Recurrent Endometrial Endometrioid Adenocarcinoma | Recurrent Endometrial Serous Adenocarcinoma | Recurrent Endometrial Undifferentiated Carcinoma | Recurrent Uterine Corpus Cancer | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell... and other conditions

United States, Canada
Pfizer

Active, not recruiting

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Renal Cell Cancer

United States, Hungary, Spain, United Kingdom, Belgium, Korea, Republic of, Canada, Israel, Denmark, Australia, Italy, Japan, France, Austria, New Zealand, Romania, Russian Federation, Netherlands, Germany, Mexico, Sweden
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Lung Adenocarcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States, Guam
National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Loxo Oncology, Inc.
Eli Lilly and Company

Recruiting

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Canada, United States, Korea, Republic of, Australia, China, Taiwan, Spain, Italy, United Kingdom, Japan, Ireland, Denmark, Hungary, Poland, Czechia, France, Israel, Singapore, Belgium, Sweden, Germany, Switzerland
Janssen Research & Development, LLC

Recruiting

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)

Carcinoma, Non-Small-Cell Lung

United States, Taiwan, Korea, Republic of, Malaysia, Turkey, France, Spain, China, Germany, Argentina
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Boehringer Ingelheim

Completed

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Taiwan, Thailand, United Kingdom
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Carcinoma, Renal Cell

Hungary, United States, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Norway, Russian Federation, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Israel
National Cancer Institute (NCI)

Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Canada
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Carcinoma, Renal Cell

Canada, United States, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Spain, Swi... and more
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)

Urothelial Carcinoma

Spain, United States, Poland, Romania, Taiwan, Ukraine, Netherlands, Mexico, Japan, France, Germany, Belgium, Greece, Russian Federation, Turkey, Canada, Israel, Italy, United Kingdom, Denmark, Korea, Republic of, Australia, Hungary
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, United States, Spain, Belgium, Austria, Czechia, Australia, Italy, Japan, Hungary, United Kingdom, Taiwan, Turkey, Germany, Canada, France, Israel, Poland, Croatia, Korea, Republic of, Ireland, Russian Federation, Singapore, Sw...
Federal Research Institute of Pediatric Hematology...

Recruiting

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015) (ALL-MB 2015)

Childhood Acute Lymphoblastic Leukemia

Armenia, Belarus, Kyrgyzstan, Russian Federation, Uzbekistan
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4)

Neuroendocrine Tumors | Advanced NET of GI Origin | Advanced NET of Lung Origin

United States, Colombia, Italy, Taiwan, United Kingdom, Belgium, Czechia, Germany, Japan, Saudi Arabia, Canada, Netherlands, Spain, Korea, Republic of, Lebanon, Austria, China, Greece, South Africa, Thailand, Hungary, Turkey, Poland, ... and more
GlaxoSmithKline

Completed

Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

Argentina, Korea, Republic of, Ukraine, Latvia, Pakistan, China, Austria, New Zealand, Poland, Russian Federation, United Kingdom, Australia, Brazil, Czech Republic, Chile, Italy, Lithuania, Slovakia, Tunisia, Estonia
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
Hoffmann-La Roche

Completed

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)

Urothelial Carcinoma

Spain, United States, Korea, Republic of, Canada, United Kingdom, Czechia, Australia, Belgium, Brazil, China, Estonia, Finland, Greece, Hong Kong, Italy, Poland, Portugal, Slovenia, Mexico, Georgia, Russian Federation, Singapore, Th... and more
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma

United States
Bristol-Myers Squibb
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Carcinoma, Non-Small-Cell Lung

Japan, China, Canada, Spain, Germany, Korea, Republic of, Austria, Brazil, Greece, France, United States, Italy, Argentina, Chile, Hungary, India, Turkey, Romania, Netherlands, Poland, Switzerland
AbbVie

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Colorectal Cancer | Non-Small Cell Lung Cancer | Advanced Solid Tumors | Gastroesophageal Adenocarcinoma

United States, Japan, Puerto Rico, Taiwan, Spain, Australia, France, Israel, Korea, Republic of, Poland
Pfizer

Terminated

Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

United States, Canada, Belgium, Italy, Spain, United Kingdom, Korea, Republic of, Netherlands, Poland, Portugal, Turkey, Taiwan, Germany, Hungary, Brazil, Hong Kong, Singapore, South Africa, China, Austria, Czech Republic, India, Is... and more
Pfizer

Completed

Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Carcinoma, Renal Cell

United States, Spain, Japan, Germany, Czechia, Russian Federation

Clinical Trials on Granuloma, Plasma Cell in China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations